CDC and FDA Expedite the Availability of Additional Doses of New RSV Immunization for Infants

Today, CDC announced the release of more than 77,000 additional doses of Beyfortus(TM) (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.